Last checked at 2 May 2023 07:00
LungLife AI, Inc. (the "Company" or "LungLife")
Confirmation of AGM
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, confirms that its Annual General Meeting ("AGM") will be held at 3:00 P.M. (BST) on Thursday 4 May 2023, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP.
For those shareholders who would like to dial into the meeting, please register by emailing LungLifeAI@walbrookpr.com or calling +44 (0)20 7933 8780 and the dial in link will be sent by email.
The Notice of AGM, Form of Direction and associated Form of Proxy are available on the Company's website and have already been posted to those shareholders who have opted out of electronic communications. The resolutions to be proposed at the AGM are summarised in the Notice of AGM. All documents are available here: https://investors.lunglifeai.com/
The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company's website as soon as practicable after the AGM.
For further information please contact:
LungLife AI, Inc. | www.lunglifeai.com |
Paul Pagano, CEO | Via Walbrook PR |
David Anderson, CFO |
|
|
|
Investec Bank plc (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7597 5970 |
Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
Goodbody (Joint Broker) Tom Nicholson / Stephen Kane |
Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420 |
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
Stephanie Cuthbert / Alice Woodings / Phillip Marriage | Mob: 07980 541 893 / 07407 804 654 / 07867 984 082 |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.